Literature DB >> 22621714

Gold(I) carbene complexes causing thioredoxin 1 and thioredoxin 2 oxidation as potential anticancer agents.

Esther Schuh1, Carolin Pflüger, Anna Citta, Alessandra Folda, Maria Pia Rigobello, Alberto Bindoli, Angela Casini, Fabian Mohr.   

Abstract

Gold(I) complexes with 1,3-substituted imidazole-2-ylidene and benzimidazole-2-ylidene ligands of the type NHC-Au-L (NHC = N-heterocyclic carbene L = Cl or 2-mercapto-pyrimidine) have been synthesized and structurally characterized. The compounds were evaluated for their antiproliferative properties in human ovarian cancer cells sensitive and resistant to cisplatin (A2780S/R), as well in the nontumorigenic human embryonic kidney cell line (HEK-293T), showing in some cases important cytotoxic effects. Some of the complexes were comparatively tested as thioredoxin reductase (TrxR) and glutathione reductase (GR) inhibitors, directly against the purified proteins or in cell extracts. The compounds showed potent and selective TrxR inhibition properties in particular in cancer cell lines. Remarkably, the most effective TrxR inhibitors induced extensive oxidation of thioredoxins (Trxs), which was more relevant in the cancerous cells than in HEK-293T cells. Additional biochemical assays on glutathione systems and reactive oxygen species formation evidenced important differences with respect to the classical cytotoxic Au(I)-phosphine compound auranofin.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22621714     DOI: 10.1021/jm300428v

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  28 in total

1.  Design, synthesis and characterisation of new chimeric ruthenium(II)-gold(I) complexes as improved cytotoxic agents.

Authors:  Lara Massai; Jacob Fernández-Gallardo; Annalisa Guerri; Annarosa Arcangeli; Serena Pillozzi; María Contel; Luigi Messori
Journal:  Dalton Trans       Date:  2015-05-21       Impact factor: 4.390

2.  DNA binding, antitumor activities, and hydroxyl radical scavenging properties of novel oxovanadium (IV) complexes with substituted isoniazid.

Authors:  Xiangwen Liao; Jiazheng Lu; Peng Ying; Ping Zhao; Yinliang Bai; Wengjie Li; Mingpei Liu
Journal:  J Biol Inorg Chem       Date:  2013-12       Impact factor: 3.358

3.  Gold(I) NHC-based homo- and heterobimetallic complexes: synthesis, characterization and evaluation as potential anticancer agents.

Authors:  Benoît Bertrand; Anna Citta; Inge L Franken; Michel Picquet; Alessandra Folda; Valeria Scalcon; Maria Pia Rigobello; Pierre Le Gendre; Angela Casini; Ewen Bodio
Journal:  J Biol Inorg Chem       Date:  2015-07-23       Impact factor: 3.358

4.  Detailed structural and spectroscopic elucidation of ferrocenium coupled N-heterocyclic carbene gold(I) complexes.

Authors:  Garrett L Reinhard; Selvakumar Jayaraman; Joshua W Prybil; Jonathan F Arambula; Kuppuswamy Arumugam
Journal:  Dalton Trans       Date:  2022-01-25       Impact factor: 4.569

5.  Luminescent iminophosphorane gold, palladium and platinum complexes as potential anticancer agents.

Authors:  Malgorzata Frik; Josefina Jiménez; Vadim Vasilevski; Monica Carreira; Andreia de Almeida; Elena Gascón; Farrah Benoit; Mercedes Sanaú; Angela Casini; María Contel
Journal:  Inorg Chem Front       Date:  2014-03-07       Impact factor: 6.569

6.  Auranofin and related heterometallic gold(I)-thiolates as potent inhibitors of methicillin-resistant Staphylococcus aureus bacterial strains.

Authors:  Yozane Hokai; Boruch Jurkowicz; Jacob Fernández-Gallardo; Nuruddinkodja Zakirkhodjaev; Mercedes Sanaú; Theodore R Muth; María Contel
Journal:  J Inorg Biochem       Date:  2014-05-28       Impact factor: 4.155

7.  N-Heterocyclic Carbene-Gold(I) Complexes Conjugated to a Leukemia-Specific DNA Aptamer for Targeted Drug Delivery.

Authors:  Weijia Niu; Xigao Chen; Weihong Tan; Adam S Veige
Journal:  Angew Chem Int Ed Engl       Date:  2016-06-17       Impact factor: 15.336

8.  Potential anticancer heterometallic Fe-Au and Fe-Pd agents: initial mechanistic insights.

Authors:  Nicholas Lease; Vadim Vasilevski; Monica Carreira; Andreia de Almeida; Mercedes Sanaú; Pipsa Hirva; Angela Casini; María Contel
Journal:  J Med Chem       Date:  2013-07-02       Impact factor: 7.446

Review 9.  A conceptually new treatment approach for relapsed glioblastoma: coordinated undermining of survival paths with nine repurposed drugs (CUSP9) by the International Initiative for Accelerated Improvement of Glioblastoma Care.

Authors:  Richard E Kast; John A Boockvar; Ansgar Brüning; Francesco Cappello; Wen-Wei Chang; Boris Cvek; Q Ping Dou; Alfonso Duenas-Gonzalez; Thomas Efferth; Daniele Focosi; Seyed H Ghaffari; Georg Karpel-Massler; Kirsi Ketola; Alireza Khoshnevisan; Daniel Keizman; Nicolas Magné; Christine Marosi; Kerrie McDonald; Miguel Muñoz; Ameya Paranjpe; Mohammad H Pourgholami; Iacopo Sardi; Avishay Sella; Kalkunte S Srivenugopal; Marco Tuccori; Weiguang Wang; Christian R Wirtz; Marc-Eric Halatsch
Journal:  Oncotarget       Date:  2013-04

10.  Genetic Interactions of STAT3 and Anticancer Drug Development.

Authors:  Bingliang Fang
Journal:  Cancers (Basel)       Date:  2014-03-06       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.